Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
Date:3/15/2011

urological product candidate OMS201 and the initiation of a program to advance a promising new antifibrinolytic agent to control surgical and traumatic bleeding," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While our primary focus remains on reporting data from our OMS103HP Phase 3 ACL program later this quarter, we also look forward to reporting data from our Phase 2b ophthalmology trial of OMS302 in the coming weeks."

Fourth Quarter and Recent Highlights

  • Omeros received $20.0 million from Vulcan and a grant award for $5.0 million from the Life Sciences Discovery Fund of Washington State (LSDF) to support the advancement of the Company's GPCR program. In return, Vulcan and LSDF have a right to receive a percentage of net proceeds generated by the GPCR program. The Vulcan funding was obtained upon closing of the agreement; the LSDF funding will be drawn down as reimbursement for future qualified expenses.
  • Expanded its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. to include the fields of addiction and compulsive disorders. Currently, Omeros is advancing PDE7 inhibitors for these indications as well as for movement disorders in collaboration with the National Institute on Drug Abuse and The Michael J. Fox Foundation, respectively.
  • Reported positive results from the Phase 1/Phase 2 clinical trial of OMS201, demonstrating that OMS201 was safe and well tolerated. OMS201 is the Company's PharmacoSurgery™ product candidate for use in urology.
  • Evaluated proof-of-concept models, and generated successful in vitro data, in connection with the series of compounds identified by Omeros that are functionally active at GPR87, an orphan GPCR linked to squamous cell carcinoma recently unlocked for drug development by the Company.
  • Announced the identification of compounds that interact selectively with two orphan GPCRs linked to pancreatic can
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
    2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
    3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
    4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
    5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
    6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
    7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
    8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
    9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
    10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
    11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is reporting ... issued a warning letter to C.R. Bard, the manufacturer of ... adequate strides to correct violations the agency found at two ... violations after the FDA cited them during Inspectional Observations that ... Bard,s Tempe, AZ , location and on ...
    (Date:7/31/2015)...  Boston Children,s Hospital physicians report the first ... their anatomy before undergoing high-risk brain procedures. The ... the brain,s blood vessels) that posed special treatment ... Journal of Neurosurgery: Pediatrics , the physicians ... resins to create custom, high-fidelity models of the ...
    (Date:7/31/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), a company ... and physician groups, today reported financial results for the ... "In the second quarter of 2015, Semler reported continued ... quarter over quarter revenue growth of 8%, and quarter ... units of 18%," said Doug Murphy-Chutorian, M.D., chief executive ...
    Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
    ... 24 PharmAthene, Inc.,(Amex: PIP ), a ... threats, announced today that the Company,is presenting two ... programs, Protexia(R) (rBChE) and Valortim(R) at the HHS,Public ... / BARDA Industry Day being held in Alexandria,VA, ...
    ... to Raise Awareness about,the Importance of Clinical Trial Participation, PHILADELPHIA, Sept. 24 ... be receptive to participating in clinical trials if ... survey of 6,000 cancer patients, 85 percent were either unaware ... trial was an option. ...
    Cached Medicine Technology:PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 7Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs 2Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs 3
    (Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest ... Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out ... makes preparing for the exam easy and painless. MDLinx offers thousands of board-exam ...
    (Date:7/31/2015)... , ... July 31, 2015 , ... According to the article published July ... the Pasadena courthouse was contained and extinguished by the city’s fire department before it caused ... building at the time of the fire, and it was a fire alarm system that ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Well-known for ... now offering wedding cakes with custom designs, making life just a little ... beautifully designed wedding cakes for each customer who orders one. , The bakery provides ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic ... potential patients alike on various plastic surgery procedures including, but not limited to, ... popular dermatology procedures like Botox and fillers. , Staying up to date ...
    (Date:7/31/2015)... ... July 31, 2015 , ... ... event geared to patients and family members, medical professionals, and researchers, covering a ... experts. The conference is a collaborative effort between the Mesothelioma Applied Research Foundation ...
    Breaking Medicine News(10 mins):Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
    ... men after bypass surgery, according to a new study done ... say whether the //results are due to medical or psychosocial ... outcomes after bypass surgery than men. Most have attributed this ... generally older, sicker, and have fewer social supports. In this ...
    ... is when symptoms have lasted for less than three ... self-management program that includes group classes, exercise sheet handouts, ... manage their back pain. ,Researchers from Indiana University ... low back pain. The program focuses on boosting confidence ...
    ... study shows hydrotherapy, or water exercise, may improve strength and ... studied more than 100 patients with osteoarthritis who were older ... first group exercised three times a week in a swimming ... did not exercise at all. Both the water and gym ...
    ... may improve strength and mobility in patients with osteoarthritis.// ... who were older than age 50. Patients were divided into ... in a swimming pool, the second exercised in a gym, ... water and gym programs focused on resistance exercises. ,Results ...
    ... lasted for less than three months. ,A new study ... sheet// handouts, and telephone follow-up calls may help patients ... from Indiana University developed a self-management program for poor, ... on boosting confidence in order to increase their motivation ...
    ... reducing the signs of aging in the neck. The procedure involves ... reduce the saggy appearance of the neck. Researchers say this new ... are often changes in the neck and face including the loss ... of fat in the neck. This causes the skin to sag. ...
    Cached Medicine News:
    ... is a dynamic new mobile tool ... to check on the compatibility of ... drugs, clear compatibility and stability results ... take clinical action based on this ...
    Providing patients and their advocates with a variety of information services and educational materials on clinical research....
    ... DrDrugs®: Drug Guide ... with over 760 Integrated ... most comprehensive, up-to-date and ... built in drug dosing ...
    Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician....
    Medicine Products: